Terri Sebree

Johnson City Medical Center — United States

Medicine · Health Sciences

18h-index1.8kcitations48works1.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Epilepsy research and treatment(12), Cannabis and Cannabinoid Research(12), Schizophrenia research and treatment(11), Genetics and Neurodevelopmental Disorders(11), Autism Spectrum Disorder Research(8)

Publications48 total

Long-term safety and tolerability of transdermal cannabidiol gel in children and adolescents with Fragile X syndrome (ZYN2-CL-017): an interim analysis of an ongoing open-label extension study
Journal of Neurodevelopmental Disorders·2025· 1 citedOpen Access
Long-Term Safety and Sustained Efficacy of ZYN002 Cannabidiol Transdermal Gel in the Treatment of Behavioral Symptoms in Children and Adolescents With Fragile X Syndrome (ZYN2-CL-017)
Journal of the American Academy of Child & Adolescent Psychiatry·2023Open Access
Role of the endocannabinoid system in fragile X syndrome: potential mechanisms for benefit from cannabidiol treatment
Journal of Neurodevelopmental Disorders·2023· 23 citedOpen Access
A randomized, controlled trial of ZYN002 cannabidiol transdermal gel in children and adolescents with fragile X syndrome (CONNECT-FX)
Journal of Neurodevelopmental Disorders·2022· 61 citedOpen Access
Adjunctive Transdermal Cannabidiol for Adults With Focal Epilepsy
JAMA Network Open·2022· 23 citedOpen Access
RECONNECT (ZYN2-CL-033): DESIGN OF A PHASE 3 TRIAL OF ZYN002 CANNABIDIOL TRANSDERMAL GEL IN CHILDREN AND ADOLESCENTS WITH FRAGILE X SYNDROME BASED UPON LEARNINGS FROM CONNECT-FX (ZYN2-CL-016)
Journal of the American Academy of Child & Adolescent Psychiatry·2021· 2 cited
LONGER-TERM TOLERABILITY AND EFFICACY OF ZYN002 CANNABIDIOL TRANSDERMAL GEL IN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDER: AN OPEN-LABEL PHASE 2 STUDY (BRIGHT [ZYN2-CL-030])
Journal of the American Academy of Child & Adolescent Psychiatry·2021· 2 cited
Safety and Tolerability of Transdermal Cannabidiol Gel in Children With Developmental and Epileptic Encephalopathies
JAMA Network Open·2021· 33 citedOpen Access
PRO1 Meaningful Change Thresholds for the Aberrant Behavior Checklist-Community Fragile X Syndrome (ABC-CFXS) in Children and Adolescents with FXS
Value in Health·2021· 2 cited
ST1 Caregiver-Perceived Behavioral Challenges in Fragile X Syndrome (FXS) and Their Measurement Using the Aberrant Behavior Checklist-Community FXS Specific (ABC-CFXS)
Value in Health·2021· 1 citedOpen Access
A Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome [CONNECT-FX (ZYN2-CL-016)]
Biological Psychiatry·2021· 5 cited
Pivotal Study of ZYN002 Cannabidiol (CBD) Transdermal Gel in Children and Adolescents With Fragile X Syndrome: Role of Methylation Status as a Correlate to Disease Severity and Prognostic Biomarker
Journal of the American Academy of Child & Adolescent Psychiatry·2020· 3 cited
Cannabidiol Transdermal Gel in Children and Adolescents with Developmental and Epileptic Encephalopathies: An Open-label Clinical Trial (1631)
Neurology·2020· 1 cited
Quality of Life and Qualitative Caregiver Assessments in Children and Adolescents with Developmental and Epileptic Encephalopathies Treated with Cannabidiol Transdermal Gel: An Open-label Clinical Trial (1664)
Neurology·2020· 1 cited
PRO10 QUALITATIVE STUDY TO ESTABLISH THE CONTENT VALIDITY OF THE ABC-CFXS FOR EVALUATION OF TREATMENT EFFICACY IN FRAGILE X SYNDROME
Value in Health·2019Open Access
A phase 1/2, open-label assessment of the safety, tolerability, and efficacy of transdermal cannabidiol (ZYN002) for the treatment of pediatric fragile X syndrome
Journal of Neurodevelopmental Disorders·2019· 99 citedOpen Access
Cannabidiol (CBD) reduces anxiety-related behavior in mice via an FMRP-independent mechanism
Pharmacology Biochemistry and Behavior·2019· 57 cited
Synthetic transdermal cannabidiol for the treatment of knee pain due to osteoarthritis
Osteoarthritis and Cartilage·2018· 48 citedOpen Access
Conversion of Cannabidiol Following Oral Administration: Authors' Response to Grotenhermen et al. DOI: 10.1089/can.2016.0036
Cannabis and Cannabinoid Research·2017· 12 citedOpen Access
Identification of Psychoactive Degradants of Cannabidiol in Simulated Gastric and Physiological Fluid
Cannabis and Cannabinoid Research·2016· 108 citedOpen Access
page 1 of 3Next →

Frequent Co-authors

Nancy Tich(10), B. Wallin(9), Randall J. Mack(8), Joseph Palumbo(8), Randi J. Hagerman(7), Jeanne V. Zborowski(7), Carol O’Neill(6), Thomas W Dobbins(6), Elizabeth Merikle(6), Donna Gutterman(6), Romeo T. Bachand(5), Mark Pierce(5), Stephen O’Quinn(5), John A. Messenheimer(5), Helen Heussler(4), Marcel O. Bonn‐Miller(4), Steven J. Siegel(4), Elizabeth Berry‐Kravis(4), Dejan B. Budimirovic(4), P. Schmitz(4)